Substance Use Counseling Intake FAQ
This FAQ collects the questions substance use counselors and treatment programs actually ask about intake forms: how 42 CFR Part 2 differs from HIPAA, ASAM Criteria levels of care, MAT informed consent under the post-MAT Act framework, court-ordered treatment dynamics, drug screening disclosures, SAMHSA Block Grant rules, CARF accreditation requirements, mandatory reporting overlap, and how the 2024 SAMHSA final rule aligned Part 2 with HIPAA. Each answer is self-contained and citation-backed. If you need a workflow that captures 42 CFR Part 2-aware ROI consent and intake with treatment-history capture in one place, Formfy is the AI form builder substance use programs use; see /guides/how-to-create-substance-use-intake-substance-use-counseling for the step-by-step build guide.
Statistics referenced: 42 CFR Part 2 is the federal Confidentiality of Substance Use Disorder Patient Records rule administered by SAMHSA. The 2024 SAMHSA final rule aligned Part 2 with HIPAA for treatment, payment, and healthcare operations. The MAT Act of 2022, included in the Consolidated Appropriations Act, eliminated the DATA-2000 X-waiver effective January 2023. The Mental Health Parity and Addiction Equity Act of 2008 governs commercial group health plan parity for substance use treatment. The ASAM Criteria, Fourth Edition (2023) is the dominant U.S. placement framework. The federal ESIGN Act and UETA (adopted in 49 states) govern e-signature enforceability.
Frequently Asked Questions
Substance use counseling intake FAQ
What is the difference between 42 CFR Part 2 and HIPAA?
42 CFR Part 2 is the federal Confidentiality of Substance Use Disorder Patient Records rule administered by SAMHSA. It is stricter than HIPAA. HIPAA permits disclosure of protected health information for treatment, payment, and healthcare operations without patient authorization in many cases. 42 CFR Part 2 historically required patient written consent for nearly any disclosure of substance use treatment information. The 2024 SAMHSA final rule aligned Part 2 more closely with HIPAA for treatment, payment, and healthcare operations but retained heightened protections for redisclosure (a Part 2-derived prohibition on redisclosure remains stricter than HIPAA) and for criminal-justice and research uses.
Which programs are subject to 42 CFR Part 2?
42 CFR Part 2 applies to federally assisted programs that hold themselves out as providing substance use disorder diagnosis, treatment, or referral. Federally assisted is defined broadly: it includes programs that receive any federal funds, hold a federal tax exemption, are licensed or registered by a federal agency (such as a DEA registration to dispense controlled substances), or are otherwise federally regulated. Most substance use treatment programs in the U.S. fall under Part 2. General medical providers who occasionally screen for or refer to substance use treatment are generally not Part 2 programs unless they hold themselves out as primarily providing substance use services.
What are the ASAM Levels of Care?
The American Society of Addiction Medicine (ASAM) Criteria, currently in their Fourth Edition (2023), define a continuum of substance use disorder treatment intensity. Levels include 0.5 (early intervention), 1.0 (outpatient), 2.1 (intensive outpatient), 2.5 (partial hospitalization), 3.1 (clinically managed low-intensity residential), 3.3 (clinically managed population-specific high-intensity residential), 3.5 (clinically managed high-intensity residential), 3.7 (medically monitored intensive inpatient), and 4.0 (medically managed intensive inpatient). The intake form should capture an assessment across the six ASAM dimensions and document the recommended level of care. ASAM placement is required by most commercial payors and state Medicaid programs for substance use prior authorization.
What is MAT informed consent?
Medication-assisted treatment (MAT) for opioid use disorder typically involves buprenorphine, methadone, or naltrexone. Informed consent must disclose the medication mechanism, expected benefits, common and serious side effects, drug interactions, the duration of treatment (often months to years), the discontinuation process (medically supervised taper), the risk of relapse if discontinued without taper, the practitioner DEA registration, and any program certifications (Opioid Treatment Program for methadone, Office-Based Opioid Treatment for buprenorphine). The intake form should also disclose that the MAT Act of 2022 eliminated the DATA-2000 X-waiver for buprenorphine, allowing any practitioner with a Schedule III DEA registration to prescribe.
How does court-ordered treatment interact with patient consent?
Court-ordered substance use treatment is common and creates a two-track consent dynamic. The court order legally compels attendance, but the patient still must provide informed consent for the specific treatment. 42 CFR Part 2 has special rules for criminal-justice referrals at 42 CFR 2.35: a patient can sign a Part 2-compliant consent allowing the program to disclose attendance and progress to the referring court, probation, or parole, and that consent can include specific Part 2 criminal-justice provisions that limit the patient revocation right while the patient remains under criminal-justice supervision. The intake form must capture the referral source and the appropriate consent.
What about insurance and Medicaid coverage?
Substance use treatment is funded through commercial insurance, Medicaid (which is the largest single payor for substance use treatment in the U.S.), Medicare, the SAMHSA Substance Use Prevention, Treatment, and Recovery Services Block Grant, state general funds, and patient self-pay. The federal Mental Health Parity and Addiction Equity Act of 2008 requires commercial group health plans to cover substance use treatment at parity with medical and surgical benefits. Medicaid coverage and prior authorization rules vary by state. The intake form should capture funding source, any state-specific prior authorization, and patient acknowledgment of out-of-pocket costs for non-covered services.
When does the program need a 42 CFR Part 2-compliant Release of Information?
The program needs a Part 2-compliant ROI any time it discloses substance use treatment information to a third party other than the patient or their personal representative. This includes referrals to primary care, communication with family members, employer-sponsored EAP follow-up, court or probation reporting, and warm handoffs to other providers. A Part 2 ROI must include the patient name, the specific disclosing party, the specific receiving party, the purpose, the specific information to be disclosed, an expiration date or event, the patient signature, and a notice that redisclosure is prohibited unless permitted by Part 2. Generic HIPAA releases do not satisfy Part 2.
What are the drug screening disclosures the intake form must include?
The intake form should disclose seven elements of the drug screening protocol. First, the type of testing (urine, oral fluid, hair, breath alcohol). Second, the frequency (random, scheduled, observed, unobserved). Third, the panel (5-panel, 10-panel, EtG for alcohol, prescription drug confirmation). Fourth, the laboratory (CLIA-certified, in-house point-of-care). Fifth, the consequence of positive results (clinical conversation, increased intensity, discharge consideration). Sixth, the consequence of refused or missed screens. Seventh, the chain-of-custody procedure. Some states regulate the use of drug screening in treatment with specific consent requirements, particularly in court-ordered cases.
How does mandatory reporting interact with 42 CFR Part 2?
42 CFR Part 2 has a specific carve-out at 42 CFR 2.12(c)(6) that permits disclosure for purposes of reporting child abuse or neglect under state law without patient consent. State child abuse and neglect mandated-reporter statutes apply to substance use counselors as licensed mental health professionals. Other mandatory disclosures (impaired driving threats, certain communicable diseases) are generally not exempt under Part 2 and require either a Part 2-compliant consent or a court order issued under 42 CFR Part 2 subpart E. The intake form should disclose both mandatory reporting overlaps in plain language and reference the specific state statutes.
What is CARF accreditation and is it required?
CARF International accredits behavioral health programs including substance use treatment, opioid treatment programs, and integrated behavioral health. The Joint Commission also accredits substance use treatment. CARF accreditation is voluntary at the federal level but is often required by state Medicaid programs, commercial payor networks, and state licensing boards as a condition of network participation or licensure. CARF accreditation drives specific intake form requirements: documentation of clinical justification for level of care, person-served involvement in treatment planning, cultural and linguistic considerations, and outcomes measurement. Programs should verify state licensing rules to determine whether accreditation is required or simply preferred.
Can a program disclose to a patient family member without consent?
Generally no. 42 CFR Part 2 historically required patient written consent for any disclosure to family members, even in routine care coordination situations where HIPAA would have permitted it. The 2024 SAMHSA final rule made limited exceptions for medical emergencies and certain routine care situations, but the default still requires patient consent. The intake form should ask the patient at admission whether they wish to authorize specific family members to receive specific types of information (attendance only, treatment progress, medication status, discharge plan) and capture a Part 2-compliant ROI for each authorized family member.
How long should substance use treatment records be retained?
Retention rules are state-specific and program-specific. The federal HIPAA baseline is six years from creation or last use. State substance use licensing boards typically require longer retention (commonly seven to ten years from last contact). 42 CFR Part 2 itself does not impose a record retention period but requires that records remain protected throughout retention. SAMHSA Opioid Treatment Programs under 42 CFR Part 8 must retain records for a minimum period set by federal and state regulation. The intake form should disclose the program retention period and the basis (state statute citation) for it.
Are e-signed substance use intake forms enforceable?
Yes. The federal ESIGN Act and UETA (adopted in 49 states) make e-signed intake and consent forms legally equivalent to wet-ink signatures. 42 CFR Part 2 specifically allows electronic signatures on Part 2 consents at 42 CFR 2.31. Tools that capture a tamper-evident audit trail with timestamps, IP addresses, and consent to electronic records produce the strongest record. Programs should verify that the e-signature platform contractually agrees to Part 2 obligations (Part 2 has stricter business associate analogs than HIPAA). Formfy, SimplePractice, and behavioral-health platforms with Part 2 contracts all meet the evidentiary bar.
What is the SAMHSA Block Grant?
The SAMHSA Substance Use Prevention, Treatment, and Recovery Services Block Grant (the SUPTRS Block Grant, formerly the Substance Abuse Prevention and Treatment Block Grant) is a federal formula grant administered by SAMHSA that distributes funds to states to support substance use prevention and treatment services. Programs receiving SUPTRS funds have specific reporting and admission requirements, including priority-population obligations (pregnant women, women with dependent children, intravenous drug users, individuals with HIV). The intake form for Block Grant-funded slots should disclose any priority-population enrollment criteria and the data reporting obligations associated with the funding stream.
How does the program handle relapse during outpatient stages?
Relapse during outpatient stages is common and clinically expected. The intake form should disclose the program approach to relapse: continued use during outpatient is generally not automatic discharge but triggers a clinical review of level-of-care match. Many programs use a step-up protocol (return to higher intensity such as IOP or PHP) rather than discharge for first relapse during outpatient. The form should disclose the practice readmission policy, the criteria for unplanned discharge (sustained continued use without willingness to step up, behavioral, financial), and the recovery support resources available even after discharge.
Can a minor consent to substance use treatment without parents?
Minor consent for substance use treatment is state-specific. Many states have specific minor consent statutes that allow minors of a designated age to consent independently to substance use disorder treatment, often at lower ages than for general mental health treatment (commonly age 12 or 13). Federal funding sources (SAMHSA Block Grant, Medicaid) generally defer to state minor consent rules. The intake form should capture which state-specific minor consent rule applies, document the basis (parent signature, court order, statutory minor self-consent), and note that 42 CFR Part 2 protections apply to the minor records once the minor has consented under state law.
How does Formfy specifically help with substance use intake forms?
Formfy lets a substance use program describe the program type, level of care, and funding mix in plain English to the AI form builder, which returns a delivery-ready intake packet with the 42 CFR Part 2 consent and ROI block, the ASAM Criteria assessment fields, the MAT informed consent (when applicable), the drug screening disclosure, the discharge planning section, and the e-signature block in a single workflow. Treatment history capture is structured for clinical review. Submission-based pricing at $19 to $199 per month covers admission volumes without per-envelope penalties. Audit trails are timestamped per signature and meet ESIGN Act and 42 CFR 2.31 evidentiary requirements. The free 15-day trial requires no credit card.
Related resources
Build a substance use intake packet in 45 seconds
Free 15-day Formfy trial. No credit card. Submission-based pricing.
Start your free trialLast verified: 2026-04-25. This page is informational; it is not legal advice. Programs should review state licensing rules, the 42 CFR Part 2 final rule (2024 update), and accreditation-specific intake requirements with counsel.